SLU-PP-332: what it is studied alongside
SLU-PP-332 is a synthetic pan-ERR agonist used as an exercise-mimetic chemical probe. This page maps the mechanisms, tissues, and models it is studied alongside, with animal-only and in vitro evidence flagged.
SLU-PP-332 is a small-molecule synthetic agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), developed as an exercise mimetic and widely used as a chemical probe for ERR activation [2][4]. It is also referred to as SLU-PP-332 ERRα/β/γ agonist in the doping-control literature [4]. The evidence block does not provide a sequence, molecular formula, or molecular weight for this compound, so none are stated here. The work around SLU-PP-332 centres on the orphan nuclear receptor family ERR (estrogen-related receptors), which regulates mitochondrial metabolism and exercise-responsive transcription [2][5].
SLU-PP-332 is studied alongside a defined set of mechanisms, tissues, and model systems: ERR signalling and its downstream gene-expression programmes, skeletal muscle and myoblast models, in vitro metabolic stability and metabolite identification, and exercise-capacity endpoints in animals. The sections below separate what has been observed in cells, what has been observed in animals, and what remains review-level or analytical. Where the evidence is animal-only or in vitro, that is stated plainly.
Research Studies
SLU-PP-332 and ERRα/β/γ agonism
SLU-PP-332 is described as a pan-ERR agonist, meaning it activates ERRα, ERRβ, and ERRγ rather than a single subtype [1][4]. ERRs are orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle [6]. In the exercise-mimetic literature, ERR activation is framed as a molecular strategy to mimic exercise-induced benefits, and SLU-PP-332 is the most widely used synthetic tool for that activation [2][5].
SLU-PP-332 and structure-activity relationships
A comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold has been reported, integrating chemical synthesis, cell-based functional assays, and downstream gene-expression profiling [2]. That work set out to clarify the structural features governing potency, efficacy, selectivity, and drug-like properties of the scaffold, which had not previously been systematically elucidated [2]. This is in vitro and cell-based work; it does not establish whole-organism effects.
SLU-PP-332 and in vitro metabolism
SLU-PP-332 has been characterized by liquid chromatography-high resolution (tandem) mass spectrometry (LC-HRMS/MS), and its in vitro metabolic transformation products have been prepared using human liver S9 fractions [1]. The same study characterized the related pan-ERR agonist SLU-PP-915 under the same analytical approach [1]. This is an analytical and in vitro metabolism study; it describes how the compound is detected and transformed in a liver-fraction system, not what it does in a living organism.
SLU-PP-332 and metabolite identification for doping control
In vitro metabolites of SLU-PP-332 have been analysed and identified for doping-control purposes [4]. The World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators in sport, and SLU-PP-332 is a small synthetic ERRα/β/γ agonist that has been considered relevant to sports drug testing programmes [1][4]. This line of work is analytical: it is about detection and identification, not about physiological outcomes.
SLU-PP-332 and skeletal muscle myoblasts from inactive women
A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women, assessing metabolic and expression changes associated with ERR activation [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. This is an ex vivo human myoblast model derived from a specific clinical population; it is not a trial of SLU-PP-332 administration in humans.
SLU-PP-332 and age-related muscle atrophy with inactivity
The same pilot work frames ERR as a potential therapeutic target to counteract muscle decline associated with aging or inactivity, on the basis that ERRs regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [3]. The population in which this was assessed was myoblasts from inactive women undergoing hip arthroplasty [3]. The evidence block does not report an in vivo muscle-atrophy endpoint for SLU-PP-332 itself.
SLU-PP-332 and metabolic syndrome models
A synthetic ERR agonist has been reported to alleviate metabolic syndrome in animal work, and SLU-PP-332 is described in that line of research as an exercise mimetic developed for the treatment of conditions including obesity and metabolic syndrome [7]. This is animal evidence; the evidence block does not provide human metabolic-syndrome data for SLU-PP-332.
SLU-PP-332 and aerobic exercise capacity
The related orally active ERR agonist SLU-PP-915 has been reported to enhance aerobic exercise capacity [6]. ERRs are described as essential for skeletal muscle adaptation to aerobic exercise and as promising targets in that context [6]. This finding concerns SLU-PP-915, not SLU-PP-332, and it is animal evidence; it is included here because the two compounds are studied alongside each other as pan-ERR agonists [1].
SLU-PP-332 and exercise-mimetic pharmacology
A systematic review has examined the physiological, molecular, and clinical evidence on pharmacological activation of ERRα/β/γ as an exercise mimetic [5]. Physical inactivity contributes to the development of chronic diseases, and ERR activation has emerged as a molecular strategy to mimic exercise-induced benefits [5]. This is review-level evidence; it synthesizes prior work rather than reporting a new experiment.
What the evidence covers, by model
| Model or system | What was assessed | Compound | Source |
|---|---|---|---|
| Cell-based functional assays and gene-expression profiling | Structure-activity relationships of the scaffold | SLU-PP-332 | [2] |
| Human liver S9 fractions | In vitro metabolic transformation products; LC-HRMS/MS characterization | SLU-PP-332 and SLU-PP-915 | [1] |
| In vitro metabolite identification | Metabolites relevant to doping control | SLU-PP-332 | [4] |
| Human myoblasts from inactive women (n = 10 inactive, n = 10 active) | Metabolic and expression changes with ERR activation | ERR targeting | [3] |
| Animal models | Metabolic syndrome endpoints | Synthetic ERR agonist | [7] |
| Animal models | Aerobic exercise capacity | SLU-PP-915 | [6] |
| Review | Physiological, molecular, and clinical evidence on ERRα/β/γ activation | ERR agonists | [5] |
SLU-PP-332 and the ERR pathway in context
Across these lines of work, SLU-PP-332 appears as a tool compound rather than a therapeutic with established human outcomes. It is studied alongside ERR signalling and downstream gene expression in cells [2], alongside analytical and metabolic characterization in liver fractions [1][4], alongside ex vivo human myoblasts from a defined clinical population [3], and alongside animal metabolic and exercise-capacity work in which the related agonist SLU-PP-915 is the compound tested [6][7]. The evidence block does not contain human dosing, human efficacy, or human safety data for SLU-PP-332.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. https://europepmc.org/article/PMC/PMC12835572
- [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. https://europepmc.org/article/PMC/PMC13112601
- [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. https://europepmc.org/article/PMC/PMC12277287
- [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. https://pubmed.ncbi.nlm.nih.gov/41688415/
- [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. https://pubmed.ncbi.nlm.nih.gov/42024694/
- [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. https://pubmed.ncbi.nlm.nih.gov/41421047/
- [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome. https://europepmc.org/article/PMC/PMC10801787